<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35607991</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Association of Human Leucocyte Antigen Class II, with viral load and immune response to Epstein-Barr virus in adult and pediatric Systemic lupus erythematosus patients.</ArticleTitle><Pagination><StartPage>1054</StartPage><EndPage>1066</EndPage><MedlinePgn>1054-1066</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033221100156</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, which is known to be associated with HLA-DRB1 and Epstein-Barr virus (EBV) infection. In the Indian subcontinent where there is high seroendemicity of EBV, we postulated that the association of this virus in adult SLE (aSLE) and pediatric SLE (pSLE) patients would be different and differentially associate with the HLA-DRB1 susceptibility and protective genes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 109 aSLE, 52 pSLE, 215 adult healthy and 63 pediatric healthy controls were recruited. HLA-DRB1 genotyping by PCR-SSP, EBV load estimation by real-time PCR and antibody profiling (IgG &amp; IgM) to EBV antigens by line blot assay were performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DRB1*15 was found predominant in pSLE patients and DRB1*03 in aSLE patients. DRB1*15/X heterozygous was predominant in overall SLE patients, although disease severity, like hypocomplementemia, higher autoantibody levels and more organ involvement was observed in *15/*15 homozygous state. EBV strongly associated with pSLE patients showing higher percent of EA-D IgG (<i>p</i> &lt; 0.0001) and p22 IgG (<i>p</i> = 0.035) along with higher viral load (<i>p</i> = 0.001) as compared to healthy controls. In addition, the higher EBV DNA load significantly associated with anti-EA-D IgG (<i>p</i> = 0.013) and DRB1*15/*15 (<i>p</i> = 0.007) in pSLE patients <i>as compared to aSLE patients.</i></AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study therefore indicates that different HLA-DRB1 allotypes confer susceptibility to SLE in children and adults and disease may be triggered by increased EBV reactivation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Prabir</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Immunopathology, 29751Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minz</LastName><ForeName>Ranjana W</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-1304-542X</Identifier><AffiliationInfo><Affiliation>Department of Immunopathology, 29751Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saikia</LastName><ForeName>Biman</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Immunopathology, 29751Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Aman</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0813-1243</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, 29751Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Shashi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Immunopathology, 29751Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Heera</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunopathology, 29751Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Surjit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Advanced Pediatric Centre, 29751Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EA-D</Keyword><Keyword MajorTopicYN="N">Epstein&#x2013;Barr virus</Keyword><Keyword MajorTopicYN="N">HLA genotype</Keyword><Keyword MajorTopicYN="N">HLA-DRB1*03</Keyword><Keyword MajorTopicYN="N">HLA-DRB1*15</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>24</Day><Hour>5</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35607991</ArticleId><ArticleId IdType="doi">10.1177/09612033221100156</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>